Compound PZ-1262, a 4-isoquinoline-sulfonamide Analog of Brexpiprazole, Produces Potential Antidepressant, Anxiolytic and Procognitive Effects in Rodent Models

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2025 Mar 11

PMID 40064751

Authors

Anna Partyka

Joanna Golebiowska

Krzysztof Marciniec

Vittorio Canale

Wojciech Trybala

Grzegorza Satala

Katarzyna Grychowska

Magdalena Jastrzebska-Wiesek

Andrzej J Bojarski

Agnieszka Nikiforuk

Wladyslawa A Daniel

Anna Wesolowska

Pawel Zajdel

Piotr Popik

Affiliations

Soon will be listed here.

Abstract

Background: Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide analogs of the modern multitarget antipsychotics aripiprazole and brexpiprazole, compounds PZ-1262 and PZ-1264. We hypothesized that the 4-isoquinolinesulfonamide moiety, derived from the structure of 5-HT receptor antagonists, would provide compounds with enhanced activity at 5-HT receptors, along with partial agonistic activity at 5-HT and D receptors.

Methods: The receptor binding profile, functional activity, and metabolic stability of PZ-1262 and PZ-1264 were evaluated through in vitro assays. Potential antipsychotic, antidepressant, anxiolytic, and pro-cognitive effects were assessed using in vivo behavioral tests in rodents.

Results: In vitro, PZ compounds demonstrated partial agonistic activity at 5-HT receptor, antagonistic activity at D and D as well as 5-HT, 5-HT and 5-HT receptors and metabolic stability. In vivo, both compounds enhanced phencyclidine-induced hyperactivity in rats and decreased immobility time in the forced swim test in mice, without influencing spontaneous locomotor activity. In the novel object recognition test in rats, they demonstrated pro-cognitive effects in phencyclidine disturbed conditions. PZ-1262 potentiated D-amphetamine-induced hyperactivity, exhibited anxiolytic-like effects in the four plates test in mice, and demonstrated significant brain penetration.

Conclusions: The complex pharmacodynamic profile translated into the useful psychotropic effects. While the compounds potentiated D-amphetamine- and phencyclidine-induced hyperactivity, this action could be regarded as a desired activating effect rather than evidence against antipsychotic-like efficacy. Present findings point to PZ-1262 as a more promising lead compound for further research.

References

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View

Zajdel P, Kos T, Marciniec K, Satala G, Canale V, Kaminski K . Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. Eur J Med Chem. 2018; 145:790-804. DOI: 10.1016/j.ejmech.2018.01.002. View

Newman-Tancredi A, Kleven M . Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011; 216(4):451-73. DOI: 10.1007/s00213-011-2247-y. View

Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer H . Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behav Brain Res. 2014; 285:165-75. DOI: 10.1016/j.bbr.2014.09.040. View

Smith A, Harmer C, Cowen P, Murphy S . The Serotonin 1A (5-HT) Receptor as a Pharmacological Target in Depression. CNS Drugs. 2023; 37(7):571-585. DOI: 10.1007/s40263-023-01014-7. View

Celada P, Bortolozzi A, Artigas F . Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013; 27(9):703-16. DOI: 10.1007/s40263-013-0071-0. View

Nikiforuk A . The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci. 2014; 25(3):367-82. DOI: 10.1515/revneuro-2014-0005. View

Goff D, Hill M, Barch D . The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2010; 99(2):245-53. PMC: 3114283. DOI: 10.1016/j.pbb.2010.11.009. View

Abbas A, Hedlund P, Huang X, Tran T, Meltzer H, Roth B . Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009; 205(1):119-28. PMC: 2821721. DOI: 10.1007/s00213-009-1521-8. View

10.

Shelton J, Bonaventure P, Li X, Yun S, Lovenberg T, Dugovic C . 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology. 2008; 56(2):448-54. DOI: 10.1016/j.neuropharm.2008.09.014. View

11.

Monti J, Leopoldo M, Jantos H, Lagos P . Microinjection of the 5-HT7 receptor antagonist SB-269970 into the rat brainstem and basal forebrain: site-dependent effects on REM sleep. Pharmacol Biochem Behav. 2012; 102(2):373-80. DOI: 10.1016/j.pbb.2012.05.012. View

12.

Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E . The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006; 5(1):25-43. DOI: 10.2174/187152706784111551. View

13.

Brosda J, Jantschak F, Pertz H . α2-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl). 2014; 231(5):801-12. DOI: 10.1007/s00213-014-3459-8. View

14.

Stahl S . Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016; 21(1):1-6. DOI: 10.1017/S1092852915000954. View

15.

Zajdel P, Marciniec K, Maslankiewicz A, Grychowska K, Satala G, Duszynska B . Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. Eur J Med Chem. 2013; 60:42-50. DOI: 10.1016/j.ejmech.2012.11.042. View

16.

Zajdel P, Marciniec K, Satala G, Canale V, Kos T, Partyka A . N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. ACS Med Chem Lett. 2016; 7(6):618-22. PMC: 4904269. DOI: 10.1021/acsmedchemlett.6b00056. View

17.

Kurczab R, Canale V, Satala G, Zajdel P, Bojarski A . Amino Acid Hot Spots of Halogen Bonding: A Combined Theoretical and Experimental Case Study of the 5-HT Receptor. J Med Chem. 2018; 61(19):8717-8733. DOI: 10.1021/acs.jmedchem.8b00828. View

18.

Partyka A, Kurczab R, Canale V, Satala G, Marciniec K, Pasierb A . The impact of the halogen bonding on D and 5-HT/5-HT receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. Bioorg Med Chem. 2017; 25(14):3638-3648. DOI: 10.1016/j.bmc.2017.04.046. View

19.

Partyka A, Jarosz J, Wasik A, Jastrzebska-Wiesek M, Zagorska A, Pawlowski M . Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. J Pharm Pharmacol. 2014; 66(12):1755-62. DOI: 10.1111/jphp.12305. View

20.

Zajdel P, Grychowska K, Mogilski S, Kurczab R, Satala G, Bugno R . Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT and 5-HT Receptor Antagonist with Antipsychotic and Procognitive Properties. J Med Chem. 2021; 64(18):13279-13298. PMC: 8474115. DOI: 10.1021/acs.jmedchem.1c00224. View